Egan-Jones Releases Risk Commentary – Shock and Awe; Fear and Loathing
NEW YORK–(BUSINESS WIRE)–Egan-Jones Ratings Company releases its latest Risk Commentary issue entitled, “Shock and Awe;…
News
Nosto named Elite Partner by Klaviyo as part of their newly-announced technology partner program
Nosto, already a best-in-class personalization provider in the Klaviyo ecosystem, achieves Elite Partner status as…
Unit4’s 2022 Business Future Index: Crisis Sees 51% Embrace Accelerated Change to Outperform Business Targets
Global data identifies action plan for business transformation around people, policy and tools London, UK,…
ALTR Announces Promotion of James Beecham to Chief Executive Officer
Company Co-founder to lead next phase of expansion and growth Austin, Texas (October 10, 2022)—…
Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV
The first episode, “Psychedelic Novelty – Before it was Cool,” introduces the company’s proprietary molecule…
Accelus Announces New Milestone with Its FlareHawk® Interbody Fusion System Surpassing 15,000 Devices Implanted
FlareHawk Expandable Lumbar Interbody Fusion System Accelus Announces New Milestone with Its FlareHawk® Interbody Fusion…
SCYNEXIS to Present Positive Interim Data from the Phase 3 FURI Study of Oral Ibrexafungerp at IDWeek 2022
JERSEY CITY, N.J., Oct. 11, 2022 (GLOBE NEWSWIRE) — SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology…
Tarsus Announces Transition Plans for Board of Directors
Co-founder and Chairman Michael Ackermann plans to transition off Board of Directors Wendy Yarno will…
SELLAS Life Sciences’ Licensee, 3D Medicines, Doses First Patient in Phase 1 Clinical Trial in China of Galinpepimut-S
NEW YORK, Oct. 11, 2022 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS)…
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
New Survey Focused on Access Limitations of Approved Autologous CAR T Therapies Reveals Only 50%…
Akoya to Report Third Quarter 2022 Financial Results on November 7th, 2022
MARLBOROUGH, Mass., Oct. 11, 2022 (GLOBE NEWSWIRE) — Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The…
Adaptive Announces Partnership with Epic to Increase Access to Minimal Residual Disease (MRD) Monitoring in Blood Cancers
Integration with the most widely used comprehensive electronic health record will expand clinician and patient…
Selecta Biosciences Announces Three Presentations at the Upcoming 29th Annual European Society of Gene and Cell Therapy (ESGCT) Conference
Data to be featured in one poster and two oral presentations WATERTOWN, Mass., Oct. 11,…
TeraImmune Receives FDA IND Clearance to Initiate Phase 1/2a Clinical Trial of TI-168 for Treatment of Hemophilia A with Refractory Inhibitors
GERMANTOWN, Md., Oct. 11, 2022 (GLOBE NEWSWIRE) — TeraImmune, Inc., a biotechnology company focused on…
Axial Therapeutics Expands Clinical Development Capabilities with Key Appointments
– Clinical development operations focused on ongoing Phase 2b clinical trial of AB-2004 in autism;…
TFF Pharmaceuticals Announces Presentation of Data Featuring Applications of Thin Film Freezing Technology at AAPS PharmSci 360 Meeting
Two Presentations Featuring Thin Film Freezing Technology Selected for the Meeting’s Special Poster Collections Demonstrates…
PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive Cancers
66% of HPV 16-positive checkpoint inhibitor refractory patients are alive at median follow up of…
Vor Bio Demonstrates Potential of Base and Sequential Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment
-Multiplex deletion of myeloid antigens CD33 and CLL-1 or CD33 and CD123 in human hematopoietic…
Cognition Therapeutics Appoints CNS Drug Development Expert to VP Clinical Development
PURCHASE, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced the…
Aquestive Therapeutics Receives Positive FDA Written Response for AQST-109 Epinephrine Sublingual Film
FDA’s End-of-Phase 2 written response provides positive feedback related to Chemistry, Manufacturing, and Controls (CMC)…